Introduction
The global antisense & RNAi therapeutics market size is anticipated to around USD 1.9 billion by 2026, this market is anticipated to grow with 7.3% CAGR during the forecast time period.
Market Dynamics
Rising examples of outside financing to direct clinical examinations relating to presentation of novel medication moieties assumes a fundamental job during the time spent new item improvement. This, alongside continuous improvements in organic vectors and nanotechnology, has energized market development.
Global human services foundations advance mindfulness and help in discovering novel treatments for treatment of various issue. Private establishments, for example, California Institute of Regenerative Medicine and ALS Association are engaged with leading preliminaries by financing research foundations and pharmaceutical associations and this is relied upon to fundamentally fuel division development. Additionally, government activities for speeding the advancement of medication conveyance stages so as to decrease infection trouble are attributive for modern development.
Market Insights
Antisense innovation gives the chance to control quality articulation for the treatment of different ailments and this is anticipated to act as a driving variable for R&D in this part. This innovation is utilized to think about quality capacity with the end goal of disease the executives by controlling the outflow of the illness causing quality. Aside from this, R&D did to ponder the treatment of remarkable neurodegenerative illnesses, for example, inherited ATTR amyloidosis is foreseen to fuel showcase development.
Antisense and RNAi therapeutics empower very explicit and successful quality hushing and therefore, a reasonable number of quality quieting drugs are in the late phases of improvement. The market is required to observe relentless development amid the figure time frame inferable from an expanding number of organizations putting resources into the improvement of particles through antisense innovation.
Since the revelation of RNAi, there have been various roads of treatment improvement utilizing RNAi. In any case, the market has grabbed next to no over the previous decade because of complexities in conveyance philosophies identified with RNAi. Advancement of more up to date nanotechnology-arranged strategies has re-implanted the market with high development potential over the conjecture time frame.
Market Segmentation
Market By Technology
- RNA Interference
- Antisense RNA
Market By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Neurodegenerative Disorders
- Genetic Disorders
- Infectious Diseases
- Other
Market By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Topical Delivery
- Other Delivery Methods
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
North America is a key market, with U.S. mirroring various RNAi therapeutics at present in formative pipelines. Various biotechnology organizations have made significantly high interests in RNAi restorative advancement. Enormous pharmaceutical engineers have gone into cooperation understandings or permitting manages various littler firms trying to gain by the normal revenue development of this market. AstraZeneca's concurrence with Ionis Pharmaceuticals is one of the striking arrangements that mirror the pattern of developing interests in antisense innovation.
Market Participants
Few of the main businesses present in the global Antisense & RNAi therapeutics market are Benitec Biopharma, GSK, Alnylam Pharmaceuticals, Sanofi-Genzyme, and Marina Biosciences. Substantial strategic initiatives undertaken by global businesses include new product launch, partnerships, and acquisitions. And also, growing R&D investments paired with technical advancements to commercialize highly efficient products are expected to offer huge growth opportunities for industry participants.
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Antisense & RNAi Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antisense & RNAi Therapeutics Market By Technology
1.2.2.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Antisense & RNAi Therapeutics Market Revenue Share By Technology in 2017
1.2.2.3. RNA Interference
1.2.2.4. Antisense RNA
1.2.2.5. Others
1.2.3. Antisense & RNAi Therapeutics Market By Application
1.2.3.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Oncology
1.2.3.3. Cardiovascular
1.2.3.4. Respiratory Disorders
1.2.3.5. Renal Diseases
1.2.3.6. Neurodegenerative Disorders
1.2.3.7. Genetic Disorders
1.2.3.8. Infectious Diseases
1.2.3.9. Others
1.2.4. Antisense & RNAi Therapeutics Market By Route of Administration
1.2.4.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.4.2. Pulmonary Delivery
1.2.4.3. Intravenous Injections
1.2.4.4. Intradermal Injections
1.2.4.5. Intraperitoneal Injections
1.2.4.6. Topical Delivery
1.2.4.7. Other Delivery Methods
1.2.5. Antisense & RNAi Therapeutics Market by Geography
1.2.5.1. Global Antisense & RNAi Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antisense & RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antisense & RNAi Therapeutics Major Manufacturers in 2017
CHAPTER 4. ANTISENSE & RNAI THERAPEUTICS MARKET BY TECHNOLOGY
4.1. Global Antisense & RNAi Therapeutics Revenue By Technology
4.2. RNA Interference
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Antisense RNA
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. ANTISENSE & RNAI THERAPEUTICS MARKET BY APPLICATION
5.1. Global Antisense & RNAi Therapeutics Revenue By Application
5.2. Oncology
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Cardiovascular
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Respiratory Disorders
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Renal Diseases
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Neurodegenerative Disorders
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Genetic Disorders
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Infectious Diseases
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Others
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. ANTISENSE & RNAI THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION
6.1. Global Antisense & RNAi Therapeutics Revenue By Route of Administration
6.2. Pulmonary Delivery
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Intravenous Injections
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Intradermal Injections
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Intraperitoneal Injections
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Topical Delivery
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Other Delivery Methods
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY
7.1. North America Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Antisense & RNAi Therapeutics Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY
8.1. Europe Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY
9.1. Asia-Pacific Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY
10.1. Latin America Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY
11.1. Middle East Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
CHAPTER 12. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET BY COUNTRY
12.1. Africa Antisense & RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antisense & RNAi Therapeutics Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. Benitec Biopharma
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. GSK
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Alnylam Pharmaceuticals
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Sanofi-Genzyme
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Marina Biosciences
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Others
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
![Antisense & RNAi Therapeutics Market (By Technology: RNA Interference [siRNA, miRNA], Antisense RNA; By Application: Oncology, Cardiovascular, Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Other; By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intradermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026](assets/images/format-png.png "Antisense & RNAi Therapeutics Market (By Technology: RNA Interference [siRNA, miRNA], Antisense RNA; By Application: Oncology, Cardiovascular, Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Other; By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intradermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026")
